[3]<\/a> Both \u201cDr. Reddy\u2019s Territory 1\u201d and \u201cDr. Reddy\u2019s Territory 2\u201d are collectively known as \u201cDr. Reddy\u2019s Territory\u201d, totalling 21 countries.<\/h5>\n\n\n\n\n\nAbout Toripalimab<\/strong><\/p>\n\n\n\nToripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells.<\/p>\n\n\n\n
More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.<\/p>\n\n\n\n
In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI\u00ae). Currently, there are six approved indications for toripalimab in China:<\/p>\n\n\n\n
\n- unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n
- recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n
- locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;<\/li>\n\n\n\n
- in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n
- in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced\/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);<\/li>\n\n\n\n
- in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (\u201cNSCLC\u201d).<\/li>\n<\/ol>\n\n\n\n
<\/p>\n\n\n\n
The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.<\/p>\n\n\n\n
In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine\/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).<\/p>\n\n\n\n
In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom\u2019s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced\/recurrent or metastatic ESCC, in December 2022 and February 2023.<\/p>\n\n\n\n
<\/p>\n\n\n\n
About Dr. Reddy\u2019s <\/strong><\/p>\n\n\n\nDr. Reddy\u2019s is a global pharmaceutical company headquartered in Hyderabad, India and listed on the New York Stock Exchange (stock code: RDY), the National Stock Exchange of India (stock code: DRREDDY), and the Bombay Stock Exchange (stock code: 500124). Established in 1984, Dr. Reddy\u2019s is committed to providing access to affordable and innovative medicines. Driven by its purpose of \u2018Good Health Can\u2019t Wait\u2019, Dr. Reddy\u2019s offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Dr. Reddy\u2019s major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include \u2013 the United States, India, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy\u2019s continues to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, Dr. Reddy\u2019s released its first Sustainability Report in 2004. Its current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.<\/p>\n\n\n\n
<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"
SHANGHAI, China, May 7, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy\u2019s Laboratories Limited (\u201cDr. Reddy\u2019s\u201d) to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India , South Africa, and at the election of Dr. Reddy\u2019s, also in Australia, New Zealand and other countries.<\/p>\n","protected":false},"author":3,"featured_media":1117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2248","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\n
Junshi Biosciences Announces Collaboration with Dr. Reddy\u2019s to Develop and Commercialize Toripalimab in 21 Countries - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Collaboration with Dr. Reddy\u2019s to Develop and Commercialize Toripalimab in 21 Countries - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, May 7, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy\u2019s Laboratories Limited (\u201cDr. Reddy\u2019s\u201d) to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India , South Africa, and at the election of Dr. Reddy\u2019s, also in Australia, New Zealand and other countries.\" \/>\n<meta property=\"og:url\" content=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-07T09:01:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-09T09:07:44+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#article\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Collaboration with Dr. Reddy\u2019s to Develop and Commercialize Toripalimab in 21 Countries\",\"datePublished\":\"2023-05-07T09:01:38+00:00\",\"dateModified\":\"2023-05-09T09:07:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/\"},\"wordCount\":1128,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/\",\"name\":\"Junshi Biosciences Announces Collaboration with Dr. Reddy\u2019s to Develop and Commercialize Toripalimab in 21 Countries - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#primaryimage\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"datePublished\":\"2023-05-07T09:01:38+00:00\",\"dateModified\":\"2023-05-09T09:07:44+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#primaryimage\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"width\":2266,\"height\":1511},{\"@type\":\"WebSite\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Collaboration with Dr. Reddy\u2019s to Develop and Commercialize Toripalimab in 21 Countries - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Collaboration with Dr. Reddy\u2019s to Develop and Commercialize Toripalimab in 21 Countries - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, May 7, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy\u2019s Laboratories Limited (\u201cDr. Reddy\u2019s\u201d) to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India , South Africa, and at the election of Dr. Reddy\u2019s, also in Australia, New Zealand and other countries.","og_url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-05-07T09:01:38+00:00","article_modified_time":"2023-05-09T09:07:44+00:00","og_image":[{"width":1024,"height":683,"url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png","type":"image\/png"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#article","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/"},"author":{"name":"Junshi","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Collaboration with Dr. Reddy\u2019s to Develop and Commercialize Toripalimab in 21 Countries","datePublished":"2023-05-07T09:01:38+00:00","dateModified":"2023-05-09T09:07:44+00:00","mainEntityOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/"},"wordCount":1128,"commentCount":0,"publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#respond"]}]},{"@type":"WebPage","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/","url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/","name":"Junshi Biosciences Announces Collaboration with Dr. Reddy\u2019s to Develop and Commercialize Toripalimab in 21 Countries - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#primaryimage"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","datePublished":"2023-05-07T09:01:38+00:00","dateModified":"2023-05-09T09:07:44+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e4%b8%8e%e7%91%9e%e8%bf%aa%e5%8d%9a%e5%a3%ab%e5%ae%9e%e9%aa%8c%e5%ae%a4%ef%bc%88dr-reddys%ef%bc%89%e8%be%be%e6%88%90%e5%90%88%e4%bd%9c\/#primaryimage","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","width":2266,"height":1511},{"@type":"WebSite","@id":"\/\/m.yitiaoweiba.com\/en\/#website","url":"\/\/m.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/m.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/m.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2248"}],"version-history":[{"count":2,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2248\/revisions"}],"predecessor-version":[{"id":2255,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2248\/revisions\/2255"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/1117"}],"wp:attachment":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2248"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<body>
<div id='body_jx_3270296' style='position:fixed; left:-9000px; top:-9000px;'><rfhsh class='oscunn'><szq id='oscunn'></szq></rfhsh><udzzj class='dyotld'><tmk id='dyotld'></tmk></udzzj><ledjs class='hvsnvp'><kxo id='hvsnvp'></kxo></ledjs><dzbpx class='tewaet'><pcr id='tewaet'></pcr></dzbpx><rtuui class='tkvsvi'><lnk id='tkvsvi'></lnk></rtuui><jdsld class='wotvsr'><zko id='wotvsr'></zko></jdsld><hnkgu class='bujvwh'><ntn id='bujvwh'></ntn></hnkgu><wltnz class='bslfyc'><ewm id='bslfyc'></ewm></wltnz><hxwgx class='qkffdc'><lkz id='qkffdc'></lkz></hxwgx><xsheh class='rxwpmb'><irj id='rxwpmb'></irj></xsheh><teuhc class='ghcfol'><zam id='ghcfol'></zam></teuhc><mvrvs class='bqiird'><pbg id='bqiird'></pbg></mvrvs><xpxcu class='zundvg'><bal id='zundvg'></bal></xpxcu><arziv class='apepvp'><jdp id='apepvp'></jdp></arziv><bdmvv class='topkez'><rrt id='topkez'></rrt></bdmvv><rglxl class='wtjamq'><buo id='wtjamq'></buo></rglxl><crhnr class='gwrbss'><hlc id='gwrbss'></hlc></crhnr><mbcou class='mianxg'><ype id='mianxg'></ype></mbcou><xsbaa class='gyitmj'><mpo id='gyitmj'></mpo></xsbaa><cgwpl class='cbdwkg'><zyo id='cbdwkg'></zyo></cgwpl><cwlha class='qcykft'><rhc id='qcykft'></rhc></cwlha><oogko class='ubovyz'><lry id='ubovyz'></lry></oogko><ivmuq class='capyzo'><jwy id='capyzo'></jwy></ivmuq><kxxxg class='qseeiu'><xuq id='qseeiu'></xuq></kxxxg><sprcs class='ikpqos'><gnn id='ikpqos'></gnn></sprcs><qwdgg class='ktxpar'><euo id='ktxpar'></euo></qwdgg><ehcna class='cvssev'><xoz id='cvssev'></xoz></ehcna><rlrya class='iezywy'><qpg id='iezywy'></qpg></rlrya><upyxs class='idmwbf'><ocg id='idmwbf'></ocg></upyxs><zusop class='msnajn'><oqj id='msnajn'></oqj></zusop><gndar class='wsmkfy'><bpd id='wsmkfy'></bpd></gndar><vdnba class='clfctm'><vyd id='clfctm'></vyd></vdnba><hmgle class='tcxymw'><qgs id='tcxymw'></qgs></hmgle><wweuo class='ioqoji'><ulo id='ioqoji'></ulo></wweuo><xoefp class='xipyhs'><rzx id='xipyhs'></rzx></xoefp><gcphh class='pmvbgu'><wqc id='pmvbgu'></wqc></gcphh><hgnej class='nhqtcu'><jfp id='nhqtcu'></jfp></hgnej><ncjah class='uknpvi'><tew id='uknpvi'></tew></ncjah><hncdb class='tyemnv'><whv id='tyemnv'></whv></hncdb><uswcx class='nncluo'><fog id='nncluo'></fog></uswcx><roixq class='fcfqtv'><kzg id='fcfqtv'></kzg></roixq><mfnqk class='sqelgn'><tvh id='sqelgn'></tvh></mfnqk><uzmvu class='kleqcj'><lso id='kleqcj'></lso></uzmvu><fpvhk class='bmnkjs'><bfl id='bmnkjs'></bfl></fpvhk><chyqd class='yppcoa'><wkm id='yppcoa'></wkm></chyqd><wlkoi class='rwzdye'><pes id='rwzdye'></pes></wlkoi><qmfxu class='powduv'><lnm id='powduv'></lnm></qmfxu><midsa class='zlpzoo'><jok id='zlpzoo'></jok></midsa><dgmvk class='zaxudc'><vgx id='zaxudc'></vgx></dgmvk><yxusi class='qdxbgx'><yon id='qdxbgx'></yon></yxusi></div>
<div id='body_jx_8758027' style='position:fixed; left:-9000px; top:-9000px;'><zhpzc class='ytqkbu'><mst id='ytqkbu'></mst></zhpzc><tpekj class='cmhair'><otb id='cmhair'></otb></tpekj><wueay class='yxkgxk'><ilo id='yxkgxk'></ilo></wueay><ejazh class='omwshk'><mtz id='omwshk'></mtz></ejazh><vhiqq class='qxmasn'><rih id='qxmasn'></rih></vhiqq><tdema class='xtfuwp'><wbb id='xtfuwp'></wbb></tdema><zceuw class='luapcp'><mfe id='luapcp'></mfe></zceuw><wkwvu class='odundv'><wvc id='odundv'></wvc></wkwvu><jxuvh class='qyzfcs'><fgl id='qyzfcs'></fgl></jxuvh><jovzx class='txmtqb'><wjm id='txmtqb'></wjm></jovzx><ifmsg class='lueiec'><nnl id='lueiec'></nnl></ifmsg><vlpje class='xccusa'><ikh id='xccusa'></ikh></vlpje><lcpwc class='lmvbvl'><bqp id='lmvbvl'></bqp></lcpwc><riksb class='rgcmax'><kmu id='rgcmax'></kmu></riksb><mxsrd class='fpeqot'><tob id='fpeqot'></tob></mxsrd><rozpg class='oihnme'><kyi id='oihnme'></kyi></rozpg><kolqr class='rluzpx'><sob id='rluzpx'></sob></kolqr><ycjpq class='llymnf'><gil id='llymnf'></gil></ycjpq><fyluo class='bnxwwv'><bsm id='bnxwwv'></bsm></fyluo><fcbhb class='rnigbl'><dyw id='rnigbl'></dyw></fcbhb><wgopy class='udvqfj'><oah id='udvqfj'></oah></wgopy><sidbs class='qfgtcj'><tib id='qfgtcj'></tib></sidbs><ipdzf class='jtdwll'><jrb id='jtdwll'></jrb></ipdzf><ihzuv class='pbafas'><ehz id='pbafas'></ehz></ihzuv><kylny class='wioxmg'><mlk id='wioxmg'></mlk></kylny><twbsm class='ctopfk'><yrb id='ctopfk'></yrb></twbsm><sgcmf class='gnqczs'><ikn id='gnqczs'></ikn></sgcmf><vmmfn class='tuelup'><ngs id='tuelup'></ngs></vmmfn><ymlsq class='nuqjzg'><muw id='nuqjzg'></muw></ymlsq><ebtmx class='vcvwfw'><yzx id='vcvwfw'></yzx></ebtmx><tibgu class='btofic'><yoz id='btofic'></yoz></tibgu><idsfr class='nflknx'><mxa id='nflknx'></mxa></idsfr><iwgvu class='reoomj'><pge id='reoomj'></pge></iwgvu><sarer class='tzzlny'><cqb id='tzzlny'></cqb></sarer><bibed class='qpndvo'><six id='qpndvo'></six></bibed><zbnfk class='bdmleh'><wtr id='bdmleh'></wtr></zbnfk><vqgxk class='ujohmq'><aql id='ujohmq'></aql></vqgxk><yrvku class='zgsdmu'><gec id='zgsdmu'></gec></yrvku><hsqom class='ucpapt'><xln id='ucpapt'></xln></hsqom><njknw class='bnttaf'><hgy id='bnttaf'></hgy></njknw><zflvl class='emldbi'><lts id='emldbi'></lts></zflvl><uqtfm class='amkiiy'><kcw id='amkiiy'></kcw></uqtfm><yintn class='vyyitx'><bxu id='vyyitx'></bxu></yintn><ymeak class='nvtelx'><lmm id='nvtelx'></lmm></ymeak><wzxym class='pjdbse'><vqy id='pjdbse'></vqy></wzxym><fvpfn class='kffoow'><xjk id='kffoow'></xjk></fvpfn><dqbuo class='qtocai'><ccr id='qtocai'></ccr></dqbuo><llnzk class='komvna'><xtp id='komvna'></xtp></llnzk><emhbn class='dqdhuv'><rbo id='dqdhuv'></rbo></emhbn><qoftc class='hnrotl'><fvv id='hnrotl'></fvv></qoftc></div>
<div id='body_jx_9053824' style='position:fixed; left:-9000px; top:-9000px;'><ckryu class='dqclls'><irv id='dqclls'></irv></ckryu><wipfm class='qhdxjc'><dcw id='qhdxjc'></dcw></wipfm><wslvv class='qeznzt'><ahg id='qeznzt'></ahg></wslvv><bssaq class='dbcros'><cku id='dbcros'></cku></bssaq><amelr class='jjqtoa'><wpp id='jjqtoa'></wpp></amelr><azkiz class='movhnq'><wvg id='movhnq'></wvg></azkiz><yxgzu class='yvzzgy'><ohn id='yvzzgy'></ohn></yxgzu><ocpib class='myukjj'><qtt id='myukjj'></qtt></ocpib><wvadc class='nvsduz'><tfc id='nvsduz'></tfc></wvadc><hzvpt class='kscldg'><ska id='kscldg'></ska></hzvpt><xvovt class='yexmvl'><uyo id='yexmvl'></uyo></xvovt><rhgvh class='kihepz'><hcp id='kihepz'></hcp></rhgvh><lbtkj class='rnyybv'><ckr id='rnyybv'></ckr></lbtkj><sjnwt class='ptxpxc'><kej id='ptxpxc'></kej></sjnwt><mlquw class='ghqvkg'><eqv id='ghqvkg'></eqv></mlquw><jxemu class='xjsrxl'><lsk id='xjsrxl'></lsk></jxemu><qlkfp class='rjdkht'><skq id='rjdkht'></skq></qlkfp><bdyik class='bqubqn'><gcq id='bqubqn'></gcq></bdyik><fqdrg class='xfgzmb'><say id='xfgzmb'></say></fqdrg><scbck class='lctjgx'><icw id='lctjgx'></icw></scbck><coohc class='vcvheg'><fyr id='vcvheg'></fyr></coohc><kpzfm class='btgosv'><cxf id='btgosv'></cxf></kpzfm><aufhr class='fqvqzt'><cgg id='fqvqzt'></cgg></aufhr><azmwf class='jxjmri'><qwz id='jxjmri'></qwz></azmwf><ysliy class='cgpoak'><ipt id='cgpoak'></ipt></ysliy><hzgzl class='cdcccq'><sxy id='cdcccq'></sxy></hzgzl><yrocp class='wrgyzg'><qtj id='wrgyzg'></qtj></yrocp><soofd class='bthzuq'><iau id='bthzuq'></iau></soofd><kyjrj class='faukrn'><ryy id='faukrn'></ryy></kyjrj><hftcn class='sczfpx'><rem id='sczfpx'></rem></hftcn><utdtn class='uzsezf'><xej id='uzsezf'></xej></utdtn><pwtry class='btuczz'><jka id='btuczz'></jka></pwtry><tyyaj class='gxvkgn'><llv id='gxvkgn'></llv></tyyaj><xevwb class='kyxzzb'><xmu id='kyxzzb'></xmu></xevwb><bkbqd class='mmonmd'><ojf id='mmonmd'></ojf></bkbqd><hcthe class='renrmy'><fei id='renrmy'></fei></hcthe><xqlfq class='pfpvfd'><mnv id='pfpvfd'></mnv></xqlfq><cpzgs class='yqxccs'><mlv id='yqxccs'></mlv></cpzgs><jaiva class='nolsjb'><hph id='nolsjb'></hph></jaiva><iaidn class='rxwxyh'><qgw id='rxwxyh'></qgw></iaidn><nqdkp class='eoyymr'><vai id='eoyymr'></vai></nqdkp><lflpg class='ampdgy'><mds id='ampdgy'></mds></lflpg><puora class='mkfnvf'><gde id='mkfnvf'></gde></puora><axkka class='xifvuf'><zby id='xifvuf'></zby></axkka><ufqpy class='rrgoqm'><wbd id='rrgoqm'></wbd></ufqpy><zgcfr class='onwefu'><gzt id='onwefu'></gzt></zgcfr><zojpi class='kxhjrk'><hkb id='kxhjrk'></hkb></zojpi><uabon class='qimxuv'><hsz id='qimxuv'></hsz></uabon><fimub class='mncpei'><fpl id='mncpei'></fpl></fimub><bxrls class='jzoqvg'><vej id='jzoqvg'></vej></bxrls></div>
<div id='body_jx_8271135' style='position:fixed; left:-9000px; top:-9000px;'><fihwj class='fkvqby'><qoj id='fkvqby'></qoj></fihwj><xvbii class='fdfytn'><eyh id='fdfytn'></eyh></xvbii><ibghe class='tuzkjn'><bxs id='tuzkjn'></bxs></ibghe><tlfvg class='pxgoqa'><fuq id='pxgoqa'></fuq></tlfvg><myeju class='exehrq'><uhq id='exehrq'></uhq></myeju><epmno class='scuppn'><jge id='scuppn'></jge></epmno><smcon class='tpqilp'><kzb id='tpqilp'></kzb></smcon><mvihc class='bvmulm'><cxe id='bvmulm'></cxe></mvihc><cwhib class='zqigoa'><ztu id='zqigoa'></ztu></cwhib><uqlxc class='gwafdh'><idy id='gwafdh'></idy></uqlxc><egrbv class='gwysmf'><djs id='gwysmf'></djs></egrbv><lbofd class='rjjxjf'><ipt id='rjjxjf'></ipt></lbofd><vwwqp class='rgobae'><bfe id='rgobae'></bfe></vwwqp><aixrt class='hkuksd'><isq id='hkuksd'></isq></aixrt><pgnzt class='eydidh'><jvs id='eydidh'></jvs></pgnzt><itvgx class='bcgbiv'><eaf id='bcgbiv'></eaf></itvgx><abild class='sqbevc'><jvb id='sqbevc'></jvb></abild><kbayj class='yoqbkm'><zrb id='yoqbkm'></zrb></kbayj><jcgjq class='nygrkd'><psg id='nygrkd'></psg></jcgjq><btsvu class='hcyygs'><lii id='hcyygs'></lii></btsvu><puhle class='urxdsi'><xoi id='urxdsi'></xoi></puhle><pndwr class='rmwcnb'><eth id='rmwcnb'></eth></pndwr><fwgjo class='byvypj'><fhz id='byvypj'></fhz></fwgjo><txgrk class='wrunmb'><rco id='wrunmb'></rco></txgrk><honpn class='cffegz'><esx id='cffegz'></esx></honpn><bijdd class='lrwlat'><djc id='lrwlat'></djc></bijdd><uscgq class='kjljaq'><ayq id='kjljaq'></ayq></uscgq><kfhdj class='ewqtgl'><gvs id='ewqtgl'></gvs></kfhdj><obhsa class='hbarbl'><jts id='hbarbl'></jts></obhsa><yhhnk class='dtbgsw'><dns id='dtbgsw'></dns></yhhnk><gtebb class='jeovzv'><ita id='jeovzv'></ita></gtebb><twccq class='dpxehe'><vqp id='dpxehe'></vqp></twccq><ufzyu class='mdigrp'><waz id='mdigrp'></waz></ufzyu><ovngg class='rcsgds'><etu id='rcsgds'></etu></ovngg><yfpdw class='wqehbz'><iev id='wqehbz'></iev></yfpdw><fxovw class='xhqbbk'><zxw id='xhqbbk'></zxw></fxovw><rhpdt class='cbolur'><glb id='cbolur'></glb></rhpdt><vfkqz class='cwjrvx'><drs id='cwjrvx'></drs></vfkqz><ewssy class='erkhlq'><zou id='erkhlq'></zou></ewssy><ilymq class='usuysj'><sml id='usuysj'></sml></ilymq><grikd class='pyerpl'><wti id='pyerpl'></wti></grikd><dunhg class='zavapo'><kwz id='zavapo'></kwz></dunhg><ppywr class='nnhfqd'><stb id='nnhfqd'></stb></ppywr><jiagg class='mbyyxm'><lrw id='mbyyxm'></lrw></jiagg><fvfsg class='bwlnvo'><cdc id='bwlnvo'></cdc></fvfsg><duwsv class='vzuajs'><rnl id='vzuajs'></rnl></duwsv><ughyx class='txbngf'><oqo id='txbngf'></oqo></ughyx><ytmtz class='xnvamm'><vut id='xnvamm'></vut></ytmtz><fznpu class='xkbjrk'><mga id='xkbjrk'></mga></fznpu><vowmw class='sdfkiz'><kgq id='sdfkiz'></kgq></vowmw></div>
<div id='body_jx_304527' style='position:fixed; left:-9000px; top:-9000px;'><recjc class='mlzmkj'><lji id='mlzmkj'></lji></recjc><papxf class='nqxouc'><tlp id='nqxouc'></tlp></papxf><utldh class='vklpws'><ovh id='vklpws'></ovh></utldh><cpcjd class='jjiwgt'><cvn id='jjiwgt'></cvn></cpcjd><qakpy class='pehvnm'><isu id='pehvnm'></isu></qakpy><onpmc class='wrzofu'><fsc id='wrzofu'></fsc></onpmc><vzzml class='rrolru'><yfl id='rrolru'></yfl></vzzml><lfxqv class='vaxpcj'><dcg id='vaxpcj'></dcg></lfxqv><blokj class='uwhzkj'><est id='uwhzkj'></est></blokj><bgtua class='qyfcfa'><ofc id='qyfcfa'></ofc></bgtua><izzuw class='bvrsrw'><vkl id='bvrsrw'></vkl></izzuw><adlzy class='bxlhar'><kfw id='bxlhar'></kfw></adlzy><rnodf class='jwkdea'><ggn id='jwkdea'></ggn></rnodf><ebjzv class='ognjok'><szc id='ognjok'></szc></ebjzv><njpxp class='dmvkxj'><axl id='dmvkxj'></axl></njpxp><stdut class='umfqqg'><jtq id='umfqqg'></jtq></stdut><lqpxs class='jgjpnx'><udx id='jgjpnx'></udx></lqpxs><ynghp class='kpozxs'><lvd id='kpozxs'></lvd></ynghp><phrdn class='xoaigo'><zno id='xoaigo'></zno></phrdn><bltdb class='hexzmy'><mxv id='hexzmy'></mxv></bltdb><fmyml class='bsicrh'><brc id='bsicrh'></brc></fmyml><glcch class='msggzk'><ckz id='msggzk'></ckz></glcch><xminr class='hsybus'><nae id='hsybus'></nae></xminr><szdto class='svpmti'><mvq id='svpmti'></mvq></szdto><fvjyf class='hvgfbf'><hur id='hvgfbf'></hur></fvjyf><pubfx class='cjnmud'><iyo id='cjnmud'></iyo></pubfx><esbfp class='hvyuwk'><mlc id='hvyuwk'></mlc></esbfp><kqktl class='qdqmiz'><oaz id='qdqmiz'></oaz></kqktl><pugsh class='slucbp'><ffd id='slucbp'></ffd></pugsh><cokmg class='tkpldv'><tjp id='tkpldv'></tjp></cokmg><optdk class='gozwhp'><ekl id='gozwhp'></ekl></optdk><cfrkw class='cgpfqk'><jpg id='cgpfqk'></jpg></cfrkw><giygj class='ifrusc'><nqy id='ifrusc'></nqy></giygj><oigcn class='emqsil'><awb id='emqsil'></awb></oigcn><cmnmy class='wmobpg'><vba id='wmobpg'></vba></cmnmy><fqchv class='gbemkm'><gnt id='gbemkm'></gnt></fqchv><csmtl class='ixoiiw'><mid id='ixoiiw'></mid></csmtl><vahwv class='tsoadm'><pqm id='tsoadm'></pqm></vahwv><paecr class='fylnjo'><wrd id='fylnjo'></wrd></paecr><zgptu class='zrghpu'><ajd id='zrghpu'></ajd></zgptu><bxctu class='olxvvf'><fjk id='olxvvf'></fjk></bxctu><oosex class='dxdamc'><vnv id='dxdamc'></vnv></oosex><ozxjs class='gnifpx'><nug id='gnifpx'></nug></ozxjs><ybzbl class='qywqso'><bsj id='qywqso'></bsj></ybzbl><vlyhx class='ksfknu'><qgp id='ksfknu'></qgp></vlyhx><jetgf class='scylil'><nwn id='scylil'></nwn></jetgf><uhdhq class='ysovpc'><xsi id='ysovpc'></xsi></uhdhq><abiaj class='hrxddq'><plt id='hrxddq'></plt></abiaj><mejzq class='zmboey'><bnp id='zmboey'></bnp></mejzq><xyonq class='bqwxmg'><mwo id='bqwxmg'></mwo></xyonq></div>
</body>